Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids

Engineered organoids by sequential introduction of key mutations could help modeling the dynamic cancer progression. However, it remains difficult to determine gene paths which were sufficient to capture cancer behaviors and to broadly explain cancer mechanisms. Here, as a case study of colorectal c...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in bioengineering and biotechnology 2020-02, Vol.8, p.12-12
Main Authors: Ping, Yanyan, Xu, Chaohan, Xu, Liwen, Liao, Gaoming, Zhou, Yao, Deng, Chunyu, Lan, Yujia, Yu, Fulong, Shi, Jian, Wang, Li, Xiao, Yun, Li, Xia
Format: Article
Language:English
Subjects:
Bioengineering and Biotechnology
colorectal cancer
engineered organoids
gene cascading paths
prioritizing
random walk with restart
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Engineered organoids by sequential introduction of key mutations could help modeling the dynamic cancer progression. However, it remains difficult to determine gene paths which were sufficient to capture cancer behaviors and to broadly explain cancer mechanisms. Here, as a case study of colorectal cancer (CRC), functional and dynamic characterizations of five types of engineered organoids with different mutation combinations of five driver genes ( , and ) showed that sequential introductions of all five driver mutations could induce enhanced activation of more hallmark signatures, tending to cancer. Comparative analysis of engineered organoids and corresponding CRC tissues revealed sequential introduction of key mutations could continually shorten the biological distance from engineered organoids to CRC tissues. Nevertheless, there still existed substantial biological gaps between the engineered organoid even with five key mutations and CRC samples. Thus, we proposed an integrative strategy to prioritize gene cascading paths for shrinking biological gaps between engineered organoids and CRC tissues. Our results not only recapitulated the well-known adenoma-carcinoma sequence model (e.g., AKST-organoid with driver mutations in , and ), but also provided potential paths for delineating alternative pathogenesis underlying CRC populations (e.g., A-organoid with mutation). Our strategy also can be applied to both organoids with more mutations and other cancers, which can improve and innovate mechanism across cancer patients for drug design and cancer therapy.
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2020.00012